SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Aug 3, 2018
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Aug. 3, 2018 · CIK: 0001506251 · Accession: 0000000000-18-024069
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226395
Letter
August 3, 2018 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 Re:Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 27, 2018 File No. 333-226395 Dear Mr. Holubiak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Alexander M. Donaldson, Esq.
Show Raw Text
August 3, 2018
Myron Holubiak
President and Chief Executive Officer
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, NJ 07016
Re:Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed July 27, 2018
File No. 333-226395
Dear Mr. Holubiak:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Alexander M. Donaldson, Esq.